| Literature DB >> 28135008 |
Safieh Ebrahimi1, Elnaz Ghorbani2, Majid Khazaei3, Amir Avan4,5, Mikhail Ryzhikov6, Kayhan Azadmanesh7, Seyed Mahdi Hassanian1,4,8.
Abstract
Interferons (INFs) elicit antiviral responses in tumor cells upon binding to cell surface receptors. Oncolytic virotherapy (OV) is an effective antitumor therapeutic approach which in combination with standard radiotherapy or chemotherapy regimens potentiates treatment responses in cancer patients. However, oncolytic viruses are susceptible to the IFN-induced antiviral state in the tumor microenvironment. A number of studies have, therefore, investigated the effects of combined therapy of IFN signaling pharmacological inhibitors with oncolytic viruses, which result in improved virus replication and oncolysis. This review summarizes the current knowledge of the mechanisms of interferon-mediated tumor resistance to oncolytic virotherapy and provides new insights regarding the effectiveness of combinatorial treatment strategies to attenuate INF-induced OV resistance for greater clinical significance in the treatment of cancer patients. J. Cell. Biochem. 118: 1994-1999, 2017.Entities:
Keywords: CANCER; INTERFERON; ONCOLYTIC VIROTHERAPY
Mesh:
Substances:
Year: 2017 PMID: 28135008 DOI: 10.1002/jcb.25917
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429